Eyepoint Pharmaceuticals Stock Analysis

Eyepoint Stock Analysis Notes

About 97.0% of the company shares are held by institutions such as insurance companies. The book value of Eyepoint Pharmaceuticals was currently reported as 4.34. The company recorded a loss per share of 2.42. Eyepoint Pharmaceuticals last dividend was issued on the 9th of December 2020. The entity had 1:10 split on the 9th of December 2020. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Eyepoint Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people. To learn more about Eyepoint Pharmaceuticals call Nancy Lurker at 617 926 5000 or check out https://eyepointpharma.com.

Eyepoint Pharmaceuticals Investment Alerts

Eyepoint Pharmaceuticals Upcoming and Recent Events

Eyepoint Largest EPS Surprises

View All Earnings Estimates

Eyepoint Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Eyepoint Pharmaceuticals Thematic Classifications

Eyepoint Stock Institutional Investors

Note, although Eyepoint Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eyepoint Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 717.02 M.

Eyepoint Profitablity

The company has Profit Margin (PM) of (2.62) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.0) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.0.

Management Efficiency

Eyepoint Pharmaceuticals has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5354) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.41 in 2025. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 439.4 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 18.2 M in 2025.

Technical Drivers

As of the 19th of July, Eyepoint Pharmaceuticals shows the Downside Deviation of 4.21, mean deviation of 3.65, and Coefficient Of Variation of 489.63. Eyepoint Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Eyepoint Pharmaceuticals Price Movement Analysis

Eyepoint Pharmaceuticals Insider Trading Activities

Eyepoint Pharmaceuticals Outstanding Bonds

Eyepoint Pharmaceuticals Predictive Daily Indicators

Eyepoint Pharmaceuticals Corporate Filings

Eyepoint Pharmaceuticals Forecast Models

Eyepoint Pharmaceuticals' time-series forecasting models are one of many Eyepoint Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eyepoint Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Eyepoint Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eyepoint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Eyepoint Pharmaceuticals. By using and applying Eyepoint Stock analysis, traders can create a robust methodology for identifying Eyepoint entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eyepoint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eyepoint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Eyepoint Pharmaceuticals stock analysis indicators help investors evaluate how Eyepoint Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Eyepoint Pharmaceuticals shares will generate the highest return on investment. By understating and applying Eyepoint Pharmaceuticals stock analysis, traders can identify Eyepoint Pharmaceuticals position entry and exit signals to maximize returns.

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.